GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Invesco European Growth Fund Comments on MorphoSys

November 11, 2013 | About:
Holly LaFon

Holly LaFon

258 followers
MorphoSys (XTER:MOR) is a German biotechnology company with a proprietary technology to develop human antibodies for specific diseases. The company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp.) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.

From Invesco European Growth Fund’s third quarter 2013 commentary.

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK